sumatriptan

(redirected from Zecuity)
Also found in: Medical.

su·ma·trip·tan

 (so͞o′mə-trĭp′tn)
n.
A triptan drug, C14H21N3O2S, used also in the form of its succinate to treat migraine headache and cluster headache.

[suma-, origin unknown + -triptan, triptan suffix; see triptan.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
Translations

sumatriptan

n sumatriptán m
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
There is no evidence that sumatriptan (Alsuma, Imitrex, Imitrex Statdose, Sumavel DosePro, Zecuity) is a human teratogen but there is a possible increase in preterm birth.
And in particular cases (Zecuity migraine patch), the FDA allowed market release as long as the manufacturer reported AEs to the agency within 15 days of receiving a complaint.
THE FOOD AND DRUG Administration is evaluating patient reports of serious burns and potential permanent scarring that have occurred with the use of the Zecuity patch (sumatriptan iontophoretic transdermal system) to relieve migraine headaches.
M2 PHARMA-June 16, 2016-Teva Pharmaceutical suspends US sales, marketing and distribution of ZECUITY
M2 EQUITYBITES-June 16, 2016-Teva Pharmaceutical suspends US sales, marketing and distribution of ZECUITY
has introduced Zecuity, described as the first and only patch system designed to provide relief from migraine.
The total purchase price includes an additional consideration of USD3.15 per share conditional on the target reaching certain milestones related to its Zecuity migraine treatment, the buyer said on 21 January when the agreement was announced.
Teva's specialty medicines segment includes several franchises, most significantly in the therapeutic areas of central nervous system (CNS) medicines, such as Copaxone, Azilect, Nuvigil and Zecuity and respiratory medicines such as ProAir HFA and QVAR.
NuPathe has developed Zecuity, the only prescription migraine patch approved by the Food and Drug Administration for the acute treatment of migraine in adults.
In addition to the initial consideration, the target's shareholders will receive additional payments of USD3.15 per share conditional on NuPathe reaching certain milestones related to its Zecuity migraine treatment, the buyer said.
M2 PHARMA-September 24, 2013-NuPathe Inc to determine safety and tolerability of single dose of ZECUITY in adolescents with acute migraine in Phase 1 study(C)2013 M2 COMMUNICATIONS